Aptahem (APTA) Q4 2025 earnings summary

Executive summary

• Fourth quarter marked by strategic progress in clinical development and business positioning, with intensified partner dialogues and increased external interest in the lead candidate Apta-1.

• Focus on cost-effective operations with a small, highly skilled team, and strengthened international compatibility.

• Aptamer-based therapies are gaining industry traction, supporting the company's differentiated approach.

Financial highlights

• Q4 operating income: 829 KSEK (790 KSEK in Q4 2024); full-year: 2,585 KSEK (3,844 KSEK in 2024).

• Result after financial items: -1,705 KSEK in Q4 (-2,890 KSEK in Q4 2024); full-year: -6,490 KSEK (-8,606 KSEK in 2024).

• Cash and cash equivalents at year-end: 2,964 KSEK (4,132 KSEK in 2024).

• Equity ratio at year-end: 98.31% (96.60% in 2024).

• Earnings per share: -0.08 SEK in Q4 (-0.23 SEK in Q4 2024); -0.31 SEK for the year (-0.69 SEK in 2024).

Outlook and guidance

• Entering 2026 with strong momentum and expectations for a breakthrough year in clinical, business, and strategic terms.

• Ongoing need for capital to advance clinical programs and partner discussions; capital raising anticipated within the next twelve months.